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Summary 
Neovascularization is observed in a spectrum of diseases such as solid tumors, diabetic retinopathy, 
and rheumatoid arthritis. It is also evident in rat collagen-induced arthritis (CIA), an animal 
model with histologic, clinical, and radiographic manifestations resembling rheumatoid arthritis. 
To evaluate the effects of angioinhibition in CIA, Louvain rats were immunized with type II 
collagen to induce arthritis and then administered an angiogenesis inhibitor, AGM-1470,  in an 
attempt to either prevent arthritis or suppress established disease. Using clinical and radiographic 
criteria, AGM-1470 prevented CIA and significantly suppressed established disease without evidence 
of immunosuppression. Histologic sections from control ankle joints manifested pannus and 
neovascularization, which were absent in experimental animals. This is the first study to investigate 
this novel agent in an autoimmune disease, and additional evaluation of this promising compound 
in other diseases that are potentially angiogenesis dependent, such as rheumatoid arthritis, might 
be warranted. 
N 
eovascularization plays  a  physiologic role  in  wound 
healing and corpus luteum development (1). Pathologic 
neovascularization is also critical for solid tumor growth, 
proliferative diabetic retinopathy, and pannus formation in 
rheumatoid arthritis (2). Inhibitors of neovascularization, or 
"angiogenesis inhibitors," have been evaluated  in vitro and 
in tumor models in vivo, although the effect of these novel 
agents on inflammatory arthritis has not been previously de- 
scribed (3). In this study, the effect of AGM-1470,  an angio- 
genesis  inhibitor, on collagen-induced arthritis (CIA) was 
examined. CIA is a T cell-dependent animal model of rheu- 
matoid arthritis in which rodents (4) and nonhuman primates 
(5) develop a polyarthritis after immunization with type II 
collagen (CII). In rats, arthritis typically appears 10-14 d post- 
CII immunization. Pathologically, CIA resembles  rheuma- 
toid arthritis with pannus formation, cartilage/bone erosions, 
and new blood vessel formation. Humoral and cellular im- 
mune responses to CII are present in both diseases (6). AGM- 
1470 is a synthetic derivative of fumagillin, a naturally oc- 
curring fungal antibiotic of Aspergilhsfumigatusfresenius.  In 
the current study, the ability of AGM-1470  to prevent or 
diminish CIA was determined by clinical, radiographic, and 
histologic methods. 
Materials and Methods 
Experimental Design.  Female  Louvain  (LOU) rats (125-150 gm) 
were used in all experimental protocols. In an attempt to induce 
arthritis, rats were immunized intradermally  using ether anesthesia 
on day 0 with 0.5 mg chick CII (Genzyme, Boston, MA) solubi- 
lized in 0.1 M acetic acid and emulsified  in IFA (Difco Laborato- 
ties, Detroit, MI) (4). Synovitis  typically  develops 10-14 d postim- 
munization in 90-100% of  control rats. AGM-1470 was solubilized 
in 10% ethanol and 5% gum arabic/normal saline mixture. 0.3 
ml of AGM-1470 was given subcutaneously  on alternate days  using 
a dose of 27 mg/kg. Four treatment protocols (A-D) were used 
with control rats receiving  no active  compound. In protocols A-C, 
AGM-1470 was initiated on day 2, before the onset of arthritis, 
in an attempt to prevent CIA. AGM-1470 was discontinued on 
day 26 (protocol A), 16 (protocol B), and 8 (protocol C). In pro- 
tocol D, AGM-1470 was instituted on day 10 (arthritis onset) and 
treatment continued to day 26 to suppress existing arthritis. 
Arthritis Assessments.  Both the incidence  and severity  of the ar- 
thritis were evaluated. Incidence  was defined as the number of rats 
that had clinical evidence  of  joint inflammation during the study 
period, and severity was quantified by scoring daily each paw in 
integers from 0 to 4 (0  =  normal, 4  =  maximum) based on in- 
creasing levels of swelling and periarticular erythema. The sum of 
the scores for all four paws was calculated  as an arthritic index (4), 
with a maximum possible score of 16 per rat. Since  CIA primarily 
affects hind limbs, scores of 6-8 represent severe arthritis. 
Radiographic scoring was assessed by the extent of  joint space 
narrowing, bone destruction, periosteal new bone formation, and 
soft tissue swelling (7). Scores were assigned as integers from 0 
to 3 per limb (0 = normal, 3 = maximum joint destruction) and 
were determined by a blinded investigator. The radiographic  joint 
index represents the sum of hind paw scores from each rat (8), with 
a maximum possible score of six per rat. Ankle joints were har- 
vested at the completion or the protocols on day 28, decalcified, 
and stained with hematoxylin and eosin. 
Cellular and Humoral Immunity.  Delayed-type  hypersensitivity 
(DTH) to native CII was quantified in vivo by a radiometric ear 
assay (8). Radiomettic ear indices >1.4, which represents >2 SD 
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responses to CII. IgG antibodies to CII were measured in selected 
serum samples obtained on day 28 by an ELISA (9). 
Statistics.  Continuous  variables were analyzed by their group 
means (student's t test) and dichotomous variables  by their propor- 
tionate group frequencies  (X  2 test). The Yates correction factor was 
used where appropriate. Results were considered significant atp < 
0.05. 
Results 
In an attempt to prevent CIA, AGM-1470 was injected 
subcutaneously using three injection protocols beginning be- 
fore the onset of CIA (protocols A-C). None of the rats in 
protocols A and B developed arthritis, and only one of nine 
rats  administered AGM-1470  in  protocol  C  had  arthritis 
(delayed in onset to day 17) compared with 28 of 30 with 
arthritis in the group control (p <  0.00000001,  prevention 
protocols A  +  B  +  C vs. controls) (Table 1). Rats that were 
treated between days 2  and 8  (protocol C) were evaluated 
for an additional 2 mo after completion of the standard 28-d 
AGM-1470 protocol. No subsequent onset of CIA was noted 
during  this  prolonged  period  of further  observation.  To 
evaluate the effect of AGM-1470 on established arthritis, the 
compound was given on alternate days from the day of ar- 
thritis onset until the end of the study (protocol D). All of 
these rats developed arthritis by day 10 and were begun on 
AGM-1470 treatment at that point.  Within  8  d  (day 17), 
there was  a  significant reduction (p  <  0.002)  in  arthritis 
severity,  which was maintained throughout the remainder 
of the study period (Fig.  1). 
Blinded radiographic scores  of the hind limbs were sig- 
nificantly lower in AGM-1470 treated rats compared with 
controls (p < 0.001)  (Table 1). Histologic evaluation of hind 
limbs obtained from control rats revealed pannus formation 
with neovascularization throughout the inflammatory  infiltrate 
(Fig.  2 A).  Neovascularization and pannus were absent in 
hind limb sections obtained from AGM-1470-treated  rats (Fig. 
2 B). The levels of sensitization to CII, as measured by DTH 
and IgG antibody levels on day 28, were high in both con- 
trol and experimental animals (Table 1). Aside from the single 
Figure 1.  Arthritis severity  in rats with established arthritis treated with 
AGM-1470.  (a) Controls; (~) AGM-1470-treated rats.  There was a 
significant diminution in arthritis  severity within 8 d after initiation of 
AGM-1470 therapy in experimental animals (group D), compared with 
arthritic controls  (Table 1,  n  =  28) (/, <  0.002),  which was sustained 
throughout the remaining study period. 
arthritic  rat,  all  experimental  animals  appeared  healthy 
throughout the study with normal weight gain and with 
normal scar formation at the immunization sites.  In addi- 
tion, there were no toxic side effects such as hair loss or in- 
fection, commonly associated  with agents that might have 
immunosuppressive or antiproliferative activity. 
Discussion 
AGM-1470 is the first angiogenesis inhibitor to be evalu- 
ated in an autoimmune disease. Using clinical, radiographic, 
and histologic criteria, it effectively  prevented and suppressed 
CIA. In previous in vivo studies of tumor growth, the com- 
pound has been shown to diminish neovascularization.  In con- 
trast, AGM-1470 had no significant effect on ascitic (angioin- 
dependent) leukemic cell growth, suggesting that it is not 
simply an antiproliferative agent. In the current study, the 
lack of neovascularization in the synovium and the excellent 
Table  1.  Arthritis  Incidence, Radiographic Scores, and Immune Responses in AGM-1470-treated  and Control Rats 
Arthritis  Radiographic  Antibody  DTH 
Protocol  incidence  index*  to CII*  to CIIS 
Controls  28/30  (93%)  4.6  0.20  3.37 
A + B  0/10 (0%) fl  0 IJ  0.17  3.75 
C  1/9  (11%) rl  ND  ND  ND 
D  10/10  (100%)  I  1.5 fl  ND  ND 
* Mean radiographic  scores at the conclusion of the study,  day 28. 
Mean OD at 490 nm of a  1:2,560 dilution. 
S Mean radiometric  ear index. 
II p  <  0.001  compared with controls. 
All rats manifested arthritis  before institution of AGM-1470  treatment. 
1136  Angiogenesis and Collagen Arthritis Figure 2.  Photomicrographs  of ankle  joints from  control  (,4) and group  A AGM-1470  (B) treated  rats. (.4) Note the proliferative  synovium  (pannus), 
inflammatory  cells, and blood  vessels,  which  are not evident  in AGM-1470-treated  rats (B). BV, blood  vessel;  C, cartilage;  P, pannus; S, synovium, x 400. 
immune responses to CII in experimental rats indicate that 
AGM-1470 also functions as an angioinhibitor in CIA and 
not as an immunosuppressant.  Angiogenesis appears  to be 
critical for both the induction and maintenance of  CIA. When 
AGM-1470 was given for a brief interval between days 2 and 
8 (protocol C), it prevented the development of synovitis for 
at least 2 mo. Given this long time frame, it is unlikely that 
the compound was slowly released from tissue stores. A more 
plausible mechanism is that angioinhibition in the first 10 d 
of CIA precluded pannus formation. This concept is sup- 
ported by the observation that blood vessels are first observed 
within the CIA synovium 5-7 d after CII immunization (10). 
Although complete reversal of existing arthritis did not occur, 
clinical severity was significantly diminished by AGM-1470, 
possibly because endothelial cell turnover is rapid in neovas- 
cularization compared with static vessels.  Angioinhibition 
may affect endothelial cells directly or via indirect stimula- 
tion/inhibition of various cytokines such as thrombospondin, 
TNF-ol,  IFN-~x2, fibroblast  growth  factor,  TGF-ot,  and 
TGF-B (11-15).  Alternatively, angioinhibitors may suppress 
proteinases, such as TIMP-1,  which are necessary for base- 
ment membrane penetration by budding endothelial cell cap- 
illary loops  (16). 
Disease-modifying antirheumatic drugs have been used to 
treat severe rheumatoid arthritis and a few have been reported 
to have minor angioinhibitory capacities in vivo (17, 18), al- 
though the significance of this is unclear since most have im- 
munosuppressive properties  as  well.  Unfortunately,  these 
agents are only partially successful in the treatment of rheu- 
matoid arthritis and have major side effects. Because of the 
efficacy of AGM-1470 in CIA, evaluation of this novel an- 
gioinhibitor in rheumatoid arthritis might be warranted. It 
could also be synergistic in combination therapies utilizing 
immunosuppressive and antiinflammatory agents. AGM-1470 
and similar compounds may, therefore, offer an entirely new 
treatment option for a spectrum of angiogenesis-dependent 
rheumatic diseases. 
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